64 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 64 of 64 clinical reviews.
An evidence-based review of alprostadil for adolescents ages 12 to 17, including the absence of an established pediatric dose, specialist evaluation, product-label limits, and urgent safety guidance.
Evidence-based alprostadil dosing guide for adults aged 30 to 49 covering Caverject intracavernosal injection and MUSE urethral suppository titration, maximum doses, and clinical protocols.
An evidence-based guide to every clinically significant drug interaction with alprostadil, covering antihypertensives, anticoagulants, vasoactive agents, PDE5 inhibitors, and more. Includes dosing context, mechanism explanations, and management strategies.
Complete 2026 guide to alprostadil (Caverject/MUSE) pricing, Alaska Medicaid coverage, compounded alprostadil legality, insurance options, and savings strategies for Alaska residents.
Find out what alprostadil (Caverject/MUSE) costs in Kansas in 2026, whether Kansas Medicaid covers it, how compounded alprostadil 503A pharmacies compare, and which insurance plans help reduce your out-of-pocket expense.
Complete guide to alprostadil pricing, Mississippi Medicaid coverage, compounded options, insurance tips, and telehealth access in MS for 2026.
A complete 2026 guide to alprostadil pricing in Utah, covering brand Caverject, MUSE suppositories, compounded 503A options, Utah Medicaid coverage rules, and how to use manufacturer savings cards to cut costs.
Compare alprostadil injection and suppository costs against PDE5 inhibitors, trimix, and penile implants. Includes per-dose pricing, efficacy data, and insurance coverage analysis.
Complete clinical dosing guide for alprostadil intracavernosal injection and urethral suppository in older adults ages 50, 64, including titration protocols, cardiovascular considerations, and polypharmacy interactions.
Evidence-based guide to alprostadil dosing for erectile dysfunction in patients with liver disease. Covers pharmacokinetics, dose adjustments, monitoring, and safety across Child-Pugh classes.
A guide to alprostadil dosing in chronic kidney disease and renal impairment, covering mechanism, intracavernosal vs. Urethral formulations, titration protocols, and safety monitoring.
Evidence-based guide to food, supplement, and nutraceutical interactions with alprostadil (Caverject, MUSE) for erectile dysfunction, including bleeding risk modifiers and blood pressure considerations.
A clinician-level review of alprostadil's emerging delivery systems, combination approaches, and pipeline agents targeting refractory erectile dysfunction beyond the current intracavernosal and intraurethral formulations.
Evidence-based guide to alprostadil dosing in men aged 65 and older, covering intracavernosal injection and intraurethral suppository titration, renal adjustment, fall-risk management, and AUA guideline recommendations.
Evidence-based monitoring protocols for alprostadil use in men 65 and older, covering renal function, cardiovascular safety, priapism risk, fall prevention, and structured dose titration.
A guide to alprostadil safety in adults aged 65 and older, covering renal considerations, fall risk, drug interactions, dose titration, and deprescribing guidance for Caverject and MUSE.
MD-level guide to alprostadil use in renal transplant, HIV, post-radical prostatectomy, spinal cord injury, and other special populations. Covers mechanism, dosing, drug interactions, and safety evidence with PubMed citations.
A deep dive into alprostadil's manufacturing complexity, documented U.S. Supply disruptions, FDA shortage filings, and what patients with refractory ED should do when their preferred formulation is unavailable.
A physician-level explanation of how alprostadil (prostaglandin E1) produces erections, from EP receptor binding through smooth-muscle relaxation, with clinical trial data and FDA-cited evidence.
Alprostadil is an on-demand medication with no traditional missed-dose risk, but dosing errors, frequency limits, and priapism thresholds require precise clinical understanding. Full MD-level guide with PubMed-cited evidence.
Evidence-based monitoring guide for alprostadil (Caverject, MUSE) in adults aged 30 to 49. Covers injection-site checks, penile fibrosis screening, blood pressure tracking, dose titration, and when to schedule follow-up visits.
Evidence-based monitoring protocols for alprostadil intracavernosal injection and MUSE urethral suppository in men aged 50-64, covering cardiovascular screening, penile assessment, dose titration, and lab surveillance.
A guide to alprostadil monitoring in men aged 18-29, covering injection technique, priapism risk, fertility considerations, dose titration, and when to escalate care.
An evidence-based guide to monitoring off-label alprostadil use in adolescents ages 12 to 17, including the pediatric evidence gap, product-specific checks, adverse-effect follow-up, and emergency thresholds.
Evidence-based monitoring schedule for alprostadil (Caverject/MUSE) therapy including required labs, penile exams, blood pressure checks, and long-term follow-up intervals.
A clinician-grade review of alprostadil off-label applications, from penile rehabilitation and trimix therapy to Raynaud's phenomenon and female sexual dysfunction, with trial-level evidence grading.
What happens when too much alprostadil is injected or inserted, how to recognize prolonged erection and systemic toxicity, and the step-by-step emergency protocol physicians follow.
Complete clinical guide to alprostadil dosing in pediatric patients under 12, covering FDA-approved indications, weight-based prostaglandin E1 protocols for congenital heart disease, and off-label considerations with primary-source citations.
A complete clinical guide to alprostadil monitoring in pediatric patients under 12, covering FDA labeling, weight-based dosing considerations, hemodynamic surveillance, and growth and development tracking.
A detailed clinical review of alprostadil safety in pediatric patients under 12, covering FDA labeling, congenital heart disease uses, dosing considerations, adverse effects, and monitoring protocols.
A physician-level review of how genetic variation in prostaglandin receptors, metabolizing enzymes, and vascular signaling pathways shapes alprostadil response, dosing, and side-effect risk in men with erectile dysfunction.
A deep dive into alprostadil pharmacokinetics covering absorption, distribution, metabolism, excretion, and mechanism of action for Caverject and MUSE formulations.
Complete clinical guide to alprostadil pregnancy and lactation safety: FDA category, mechanism, pharmacokinetics, partner-exposure risk, and prescribing guidance for Caverject and MUSE.
A clinical guide to alprostadil regulatory approvals, brand availability, and prescribing frameworks across the United States, European Union, Canada, and the United Kingdom.
A guide to alprostadil safety in men aged 30 to 49, covering injection-site reactions, priapism risk, contraindications, dosing protocols, and how intracavernosal versus intraurethral delivery compare on the safety profile.
A guide to alprostadil safety for men aged 18, 29, covering injection technique, priapism risk, fertility considerations, dosing, and how to integrate on-demand therapy into an active young-adult lifestyle.
An evidence-based review of alprostadil safety for adolescents ages 12 to 17, including the pediatric evidence gap, product-specific risks, priapism response, and specialist safeguards.
A physician-level review of alprostadil safety signals, FDA regulatory actions, post-market surveillance data, and clinical risk management for Caverject and MUSE.
Step-by-step alprostadil intracavernosal injection and MUSE urethral suppository technique, with dosing, mechanism, safety data from Linet et al. (NEJM 1996), and guidance for men with refractory erectile dysfunction.
Evidence-based guide to storing alprostadil intracavernosal injections and MUSE urethral suppositories, including temperature requirements, reconstituted solution stability, and shelf-life data from FDA labeling and primary literature.
Evidence-based alprostadil dosing guide for young adults aged 18-29, covering Caverject intracavernosal injection and MUSE urethral suppository titration, safety monitoring, and fertility considerations.
A clinical history of alprostadil for erectile dysfunction, from prostaglandin E1 discovery through FDA approval of Caverject and MUSE, with mechanism of action and trial evidence.
A guide to discontinuing alprostadil injections and urethral suppositories, covering taper strategies, rebound physiology, transition to oral PDE5 inhibitors, and when stopping is the right clinical move.
A complete guide to Aetna (CVS Health) coverage of alprostadil (Caverject/MUSE) for erectile dysfunction, including prior authorization criteria, step therapy requirements, formulary tier, and appeal strategies.
A detailed guide to Anthem (Elevance Health) coverage for alprostadil (Caverject/MUSE), including prior authorization criteria, formulary tier, step therapy requirements, appeal strategies, and cost options.
A clinical guide to BCBS Federated coverage of alprostadil (Caverject/MUSE) for erectile dysfunction, including prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A clinical and insurance guide covering Cigna's prior-authorization criteria, formulary tier, step-therapy requirements, appeal process, and out-of-pocket costs for alprostadil (Caverject / MUSE) for erectile dysfunction.
A detailed guide to Kaiser Permanente's formulary status, prior authorization criteria, step therapy requirements, and appeal process for alprostadil (Caverject/MUSE) for erectile dysfunction.
A clinical guide to Medicare Advantage coverage, formulary tiers, prior authorization, step therapy, and appeal pathways for alprostadil (Caverject/MUSE) for erectile dysfunction.
A state-by-state breakdown of Medicaid coverage for alprostadil injections and suppositories, including prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A complete guide to TRICARE coverage of alprostadil (Caverject and MUSE) for erectile dysfunction, including formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A detailed guide to UnitedHealthcare coverage for alprostadil (Caverject and MUSE), including formulary tier, prior authorization criteria, step therapy rules, appeal pathways, and cost-saving options for men with erectile dysfunction.
A complete clinical guide to obtaining an alprostadil prescription in California, covering telehealth options, compounding pharmacies, labs, prior authorization, and real dosing data.
A guide covering telehealth prescribing, pharmacy options, prior authorization, and dosing for alprostadil (Caverject/MUSE) in Georgia.
A complete guide to obtaining alprostadil (Caverject or MUSE) in Hawaii, covering telehealth prescribing, pharmacy options, labs, prior authorization, and dosing for erectile dysfunction.
A complete guide to obtaining an alprostadil prescription in Montana, including telehealth options, pharmacy access, dosing, labs, and prior authorization requirements.
A guide to obtaining an alprostadil prescription in Nevada, covering telehealth options, 503A compounding pharmacies, prior authorization, and clinical dosing for refractory erectile dysfunction.
A complete guide to obtaining an alprostadil prescription in New Mexico, including telehealth options, pharmacy access, compounding rules, and what to expect at your first appointment.
A guide covering telehealth access, prescriptions, compounding pharmacies, prior authorization, and step-by-step instructions for obtaining alprostadil in North Carolina.
A complete guide to obtaining an alprostadil prescription in South Dakota via telehealth or in-person, including pharmacy options, compounding rules, and insurance coverage.
Showing the first 60 matches. Use search or filters to narrow the library.